Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: A retrospective study

Respiration

Volumn 86, Issue 5, 2013, Pages 376-383

  Brill, Anne Kathrin ^a   Ott, Sebastian R ^a   Geiser, Thomas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Interstitial lung disease; Mycophenolate; Pulmonary function; Sarcoidosis; Steroid sparing agent

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLIXIMAB; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PREDNISOLONE;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC PULMONARY SARCOIDOSIS; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG SARCOIDOSIS; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADD ON THERAPY; ANTIBIOTIC THERAPY; ARTERIAL OXYGEN TENSION; CORTICOSTEROID THERAPY; DRUG TOLERABILITY; DYSPNEA; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEOPLASM; PRESCRIPTION; RELAPSE; RETROSPECTIVE STUDY; SYSTEMIC THERAPY;

ADULT; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY;

EID: 84897486712     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000345596     Document Type: Article

References (32)

1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, et al. ATS/ ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
2. Baughman RP, Lower EE: Who dies from sarcoidosis and why? Am J Respir Crit Care Med 2011; 183: 1446-1447.
3. York EL, Kovithavongs T, Man SF, Rebuck AS, Sproule BJ: Cyclosporine and chronic sarcoidosis. Chest 1990; 98: 1026-1029. (Pubitemid 20355530)
4. Demeter SL: Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 1988; 94: 202-203.
5. Lower EE, Baughman RP: The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299: 153-157. (Pubitemid 20085232)
6. Zabel P, Entzian P, Dalhoff K, Schlaak M: Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669. (Pubitemid 27216674)
7. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U: Treatment of chronic sarcoidosis with an zathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
8. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802. (Pubitemid 44511661)
9. Hostettler KE, Studler U, Tamm M, Brutsche MH: Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-224.
10. Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y, Kaneko T, Murakami T, Takeuchi K, Takeyoshi I, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77: 1661-1667. (Pubitemid 38780531)
11. Eskin-Schwartz M, David M, Mimouni D: Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin 2011; 29: 555-559.
12. Howard J, Hoffbrand AV, Prentice HG, Mehta A: Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117: 712- 715. (Pubitemid 34539252)
13. Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM: Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther 2010; 12:R208.
14. Pawate S, Moses H, Sriram S: Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102: 449-460.
15. Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, Vukusic S, Seve P: Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76: 1168-1172.
16. Kouba DJ, Mimouni D, Rencic A, Nousari HC: Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148: 147-148. (Pubitemid 36114877)
17. O'Connor AS, Navab F, Germain MJ, Freeman JK, Mulhern JG, O'Shea MH, Lipkowitz GS, Madden RL, Braden GL: Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil. Dig Dis Sci 2003; 48: 2191-2195. (Pubitemid 38037308)
18. Moudgil A, Przygodzki RM, Kher KK: Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 2006; 21: 281-285. (Pubitemid 43115886)
19. Kilmartin DJ, Forrester JV, Dick AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998; 352: 35-36. (Pubitemid 28306570)
20. Bhat P, Cervantes-Castaneda RA, Doctor PP, Anzaar F, Foster CS: Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17: 185-190.
21. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968. (Pubitemid 41632054)
22. Renzetti AD Jr EG, et al. Evaluation of impairment/ disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133: 1205-1209. (Pubitemid 16090038)
23. Scadding JG: Sarcoidosis, with special reference to lung changes. Br Med J 1950; 1: 745- 753.
24. Newman LS, Rose CS, Maier LA: Sarcoidosis. N Engl J Med 1997; 336: 1224-1234. (Pubitemid 27183653)
25. Zwerner J, Fiorentino D: Mycophenolate mofetil. Dermatol Ther 2007; 20: 229-238. (Pubitemid 350029312)
26. Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, Chapman JT, Culver DA: Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150.
27. Kamphuis LS, Lam-Tse WK, Dik WA, van Daele PL, van Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van Laar JA, Bastiaans J, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184: 1214-1216.
28. Robson R, Cecka JM, Opelz G, Budde M, Sacks S: Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960. (Pubitemid 43923957)
29. Dandel M, Jasaityte R, Lehmkuhl H, Knosalla C, Hetzer R: Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Transplant Proc 2009; 41: 2585-2588.
30. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr, McLennan G, Bresnitz EA, DePalo L, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 204-211. (Pubitemid 37351542)
31. Nagai S, Shigematsu M, Hamada K, Izumi T: Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999; 5: 293-298.
32. Mana J, Salazar A, Manresa F: Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration 1994; 61: 219-225. (Pubitemid 24262454)